Physician profile
Michael J Goretsky
NPI 1467466961
$3,056.22
in general payments reported to CMS, 2019-2025
13 companies · $52.85 in 2025
The $52.85 reported for 2025 was less than what a typical Pediatric Surgery provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.66 · 2021: $1,097 · 2022: $92.83 · 2023: $472 · 2024: $1,304 · 2025: $52.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718 · Travel and Lodging: $612 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.60 |
| Travel and Lodging | $611.70 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aegis Spine, INC. | $1,111.70 | 2024 | |
| Zimmer Biomet Holdings, INC. | $1,111.66 | 2019-2021 | |
| Stryker Corporation | $198.97 | 2023 | Spy-Phi System |
| Asensus Surgical, INC. | $137.96 | 2023 | Senhance |
| Genzyme Corporation | $135.29 | 2023 | |
| Qol Medical, LLC | $90.10 | 2024 | Sucraid |
| Ethicon US, LLC | $55.83 | 2022 | |
| Kerecis Limited | $51.73 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Medtronic, INC. | $39.88 | 2024-2025 | Endo Gia Ultra, Signia |
| Atricure, INC. | $37.00 | 2022 | |
| Avita Medical Americas, LLC | $33.13 | 2025 | Cohealyx, Recell, Permeaderm |
| Solventum Corporation | $30.54 | 2024 | V.A.C. Granufoam, V.A.C. Dermatac |
| Bard Peripheral Vascular, INC. | $22.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goretsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.